Core Insights - 2025 was a pivotal year for the company, focusing on improving financial flexibility, reorganizing operations, and clarifying long-term strategic direction [1][3] - The company completed a comprehensive refinancing in December, extending debt maturity to 2021 and reducing annual debt service to $5 million, generating $3 million in annual cash savings [3][18] - The company reported fourth quarter revenue of $23.7 million, exceeding guidance, with a gross margin of 60% and adjusted EBITDA of $3.8 million, reflecting a 27% year-over-year growth [4][11] Financial Performance - Fourth quarter revenue was $23.7 million, slightly below the $24.6 million reported in Q4 2024, impacted by a 43-day government shutdown [10] - Gross margin improved to 59.7%, up 260 basis points from 57.1% in Q4 2024, marking the highest gross margin in the last seven quarters [11] - Full year revenue decreased to $86.6 million from $94.1 million, primarily due to tariffs and delayed NIH funding [12] - Adjusted EBITDA for the full year increased by 12.5% to $8.1 million, driven by cost reductions and improved expense management [13] Strategic Initiatives - The company is transitioning from a traditional life science tools provider to a leader in translational science, targeting the $10 billion translational science market [6] - Key priorities include leading the translational science bridge, accelerating high-margin innovation, expanding consumables and recurring revenue, and maintaining operational excellence [7][8] - The company aims to increase the proportion of recurring revenue, currently at approximately 55%, by focusing on higher-margin consumables and services [7] Outlook for 2026 - The company forecasts low single-digit revenue growth and high single-digit adjusted EBITDA growth for 2026, driven by higher-margin new product innovations [8][21] - Full year guidance for 2026 includes revenue growth of 2% to 4%, gross margin of 58% to 60%, and adjusted EBITDA growth of 6% to 10% [21] - The company expects to see a positive impact from NIH funding approvals towards the end of Q1 and into Q2 2026 [24][25] Market Position - The company is well-positioned to create long-term shareholder value with a technically deep global team, a refreshed board, and improved financial flexibility [9] - The Asia Pacific region showed a 10% year-over-year revenue increase in Q4, indicating a potential turnaround after previous challenges [29] - The company ended the year with the highest backlog in over two years, suggesting strong future demand [30]